secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001193125-24-068566
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron CEO Manuel Aivado resigns; President Brian Windsor named CEO effective March 11, 2024
--------------------------------------------------------------------------------

- Manuel Aivado steps down as CEO effective March 11, 2024, remains on the Board.
- Brian Windsor, previously President and COO since October 2023, appointed CEO and director.
- Windsor led Lung Therapeutics prior to its acquisition by Aileron in October 2023.
- Aivado receives severance: 18 months base salary, 1.5x target bonus, equity acceleration, COBRA.
- Resignation is not due to any disagreement with company operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/0001193125-24-068566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524068566/d787456d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-068566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer